search
Back to results

Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects

Primary Purpose

Asthma

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
FP
SFC
Placebo
Sponsored by
GlaxoSmithKline
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring asthma, allergen challenge, IL-5, eosinophils

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Informed consent.
  • Outpatient.
  • Male or non-pregnant/non-lactating female.
  • Aged 18-55.
  • Diagnosis of asthma.
  • Pre-bronchodilatory FEV1 > 75% predicted.
  • Using inhaled short-acting beta-2-agonists (SABA) with no inhaled corticosteroids.
  • Judged capable of withholding SABA for at least 6 hours prior to visits.
  • Reversibility of >12% and 200mL or PC20 of <8mg/mL.
  • Demonstration of atopy

Exclusion Criteria:

  • History of life-threatening asthma.
  • Use of proscribed asthma medications.
  • Use of anti-histamines or potent inhibitors of CYP3A4.
  • Respiratory tract infection.
  • Asthma exacerbation with 4 weeks of Visit 1.
  • Subjects with exercise induced asthma only.
  • Concurrent respiratory disease.
  • Other clinically significant, uncontrolled condition or disease.
  • Use of any investigational drug within 30 days.
  • Allergic to beta-2-agonists, inhaled corticosteroids or excipients.
  • Positive pregnancy test.
  • Using immunosuppressive medications.
  • Milk protein allergy.
  • Factors likely to interfere with attendance.
  • Current smokers or ex-smokers with a history of >10 pack years.
  • Affiliation wih Investigator site.
  • Medications that may affect the course of asthma or interact with sympathomimetic amines.

Sites / Locations

  • GSK Investigational Site
  • GSK Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Sequence 1: FP, SFC, Placebo

Sequence 2: Placebo, SFC, FP

Sequence 3: SFC, FP, Placebo

Sequence 4: SFC, Placebo, FP

Sequence 5: FP, Placebo, SFC

Sequence 6: Placebo, FP, SFC

Arm Description

Fluticasone Propionate (FP) 100 micrograms (mcg) twice daily (BID) in the first treatment period: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID in the second treatment period: Placebo in the third treatment period

Placebo in the first treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period

Salmeterol/Fluticasone Propionate 50/100 Combination mcg BID in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Placebo in the third treatment period

Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the first treatment period: Placebo in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period

Fluticasone Propionate 100 mcg BID in the first treatment period: Placebo in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period

Placebo in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period

Outcomes

Primary Outcome Measures

Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 35
Number of peripheral blood eosinophils measured from blood draws

Secondary Outcome Measures

Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 14
Number of peripheral blood eosinophils measured from blood draws
Weighted Mean Change From Baseline Over 0-6 Hours in Serum IL-5 Post-Allergen Challenge on Day 35
Amount of serum interleukin (IL)-5 measured from blood draws
Weighted Mean Change From Baseline Over 0-6 Hours in Serum IL-5 Post-Allergen Challenge on Day 14
Amount of serum IL-5 measured from blood draws

Full Information

First Posted
August 16, 2007
Last Updated
November 3, 2016
Sponsor
GlaxoSmithKline
search

1. Study Identification

Unique Protocol Identification Number
NCT00517634
Brief Title
Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects
Official Title
A 12-week, Randomised, Double-blind, Placebo-controlled, Three-period, Cross-over Pilot Study Comparing the Effect of Salmeterol/Fluticasone Propionate, Fluticasone Propionate and Placebo on Perpheral Blood Eosinophils and Serum IL-5 in Response to Allergen Challenge in Asthma Subjects When Allergen Challenge is Administered at 1 Hour or 11-12 Hours Post-dose of the Dosing Interval
Study Type
Interventional

2. Study Status

Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
August 2007 (undefined)
Primary Completion Date
July 2008 (Actual)
Study Completion Date
July 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the present study is to investigate whether the effects of salmeterol in combination with fluticasone propionate on blood markers of airway inflammation are maintained after chronic dosing and whether the effect is influenced by the time of allergen challenge relative to the time of dosing.
Detailed Description
A 12-week, randomised, double-blind, placebo-controlled, three-period, cross-over pilot study comparing the effect of salmeterol/fluticasone propionate, fluticasone propionate and placebo on perpheral blood eosinophils and serum IL-5 in response to allergen challenge in asthma subjects when allergen challenge is administered at 1 hour or 11-12 hours post-dose of the dosing interval

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
asthma, allergen challenge, IL-5, eosinophils

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
23 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sequence 1: FP, SFC, Placebo
Arm Type
Experimental
Arm Description
Fluticasone Propionate (FP) 100 micrograms (mcg) twice daily (BID) in the first treatment period: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID in the second treatment period: Placebo in the third treatment period
Arm Title
Sequence 2: Placebo, SFC, FP
Arm Type
Experimental
Arm Description
Placebo in the first treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
Arm Title
Sequence 3: SFC, FP, Placebo
Arm Type
Experimental
Arm Description
Salmeterol/Fluticasone Propionate 50/100 Combination mcg BID in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Placebo in the third treatment period
Arm Title
Sequence 4: SFC, Placebo, FP
Arm Type
Experimental
Arm Description
Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the first treatment period: Placebo in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
Arm Title
Sequence 5: FP, Placebo, SFC
Arm Type
Experimental
Arm Description
Fluticasone Propionate 100 mcg BID in the first treatment period: Placebo in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
Arm Title
Sequence 6: Placebo, FP, SFC
Arm Type
Experimental
Arm Description
Placebo in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
Intervention Type
Drug
Intervention Name(s)
FP
Intervention Description
Fluticasone Propionate 100 mcg BD
Intervention Type
Drug
Intervention Name(s)
SFC
Intervention Description
Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Matching Placebo
Primary Outcome Measure Information:
Title
Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 35
Description
Number of peripheral blood eosinophils measured from blood draws
Time Frame
0-6 hours post allergen challenge, 10-11 hours post treatment, Day 35
Secondary Outcome Measure Information:
Title
Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 14
Description
Number of peripheral blood eosinophils measured from blood draws
Time Frame
0-6 hours, post allergen challenge, 1 hour post treatment, Day 14
Title
Weighted Mean Change From Baseline Over 0-6 Hours in Serum IL-5 Post-Allergen Challenge on Day 35
Description
Amount of serum interleukin (IL)-5 measured from blood draws
Time Frame
0-6 hours post allergen challenge, 10-11 hours post treatment, Day 35
Title
Weighted Mean Change From Baseline Over 0-6 Hours in Serum IL-5 Post-Allergen Challenge on Day 14
Description
Amount of serum IL-5 measured from blood draws
Time Frame
0-6 hours post allergen challenge, 1 hour after dosing, Day 14

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Informed consent. Outpatient. Male or non-pregnant/non-lactating female. Aged 18-55. Diagnosis of asthma. Pre-bronchodilatory FEV1 > 75% predicted. Using inhaled short-acting beta-2-agonists (SABA) with no inhaled corticosteroids. Judged capable of withholding SABA for at least 6 hours prior to visits. Reversibility of >12% and 200mL or PC20 of <8mg/mL. Demonstration of atopy Exclusion Criteria: History of life-threatening asthma. Use of proscribed asthma medications. Use of anti-histamines or potent inhibitors of CYP3A4. Respiratory tract infection. Asthma exacerbation with 4 weeks of Visit 1. Subjects with exercise induced asthma only. Concurrent respiratory disease. Other clinically significant, uncontrolled condition or disease. Use of any investigational drug within 30 days. Allergic to beta-2-agonists, inhaled corticosteroids or excipients. Positive pregnancy test. Using immunosuppressive medications. Milk protein allergy. Factors likely to interfere with attendance. Current smokers or ex-smokers with a history of >10 pack years. Affiliation wih Investigator site. Medications that may affect the course of asthma or interact with sympathomimetic amines.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53792
Country
United States
Facility Name
GSK Investigational Site
City
Manchester
ZIP/Postal Code
M23 9QZ
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Links:
URL
https://www.clinicalstudydatarequest.com
Description
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Available IPD and Supporting Information:
Available IPD/Information Type
Individual Participant Data Set
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
HZA109912
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Annotated Case Report Form
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
HZA109912
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Study Protocol
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
HZA109912
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Statistical Analysis Plan
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
HZA109912
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Clinical Study Report
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
HZA109912
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Dataset Specification
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
HZA109912
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register
Available IPD/Information Type
Informed Consent Form
Available IPD/Information URL
https://www.clinicalstudydatarequest.com
Available IPD/Information Identifier
HZA109912
Available IPD/Information Comments
For additional information about this study please refer to the GSK Clinical Study Register

Learn more about this trial

Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects

We'll reach out to this number within 24 hrs